Long non-coding RNAs in ovarian cancer

Zhan, Lei; Li, Jun; Wei, Bing

doi:10.1186/s13046-018-0793-4

Cited by 80 publications

(73 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To further understand the role of this CAM in regulating cancer metastasis, other future experiments may include: (a) searching for the heterophilic ligands or partners of METCAM/MUC18 [ 9 ], (b) systematic investigation of the three mechanisms in the tumor and metastasis dormancy (for examples, what are the key members involved in intrinsic growth inhibition, immunological suppression, and/or reducing angiogenesis?) [ 41 ], (c) possible miRNAs [ 42 ] and long non-coding RNAs [ 43 ] upstream and downstream of METCAM/MUC18 involved in the process and (d) the transcriptional control in the processes [ 9 ]. Precaution should be taken that a complete picture may only be possibly constructed after all the above studies are successfully executed.…”

Section: Discussionmentioning

confidence: 99%

METCAM/MUC18 Decreases the Malignant Propensity of Human Ovarian Carcinoma Cells

2018

IJMS

View full text Add to dashboard Cite

METCAM/MUC18 is an integral membrane cell adhesion molecule (CAM) in the Ig-like gene super-family. It can carry out common functions of CAMs which is to perform intercellular interactions and interaction of cell with extracellular matrix in tumor microenvironment, to interact with various signaling pathways and to regulate general behaviors of cells. We and other two groups previously suggested that METCAM/MUC18 probably be utilized as a biomarker for predicting the malignant tendency of clinical ovarian carcinomas, since METAM/MUC18 expression appears to associate with the carcinoma at advanced stages. It has been further postulated to promote the malignant tendency of the carcinoma. However, our recent research results appear to support the conclusion that the above positive correlation is fortuitous; actually METCAM/MUC18 acts as a tumor and metastasis suppressor for the ovarian carcinoma cells. We also suggest possible mechanisms in the METCAM/MUC18-mediated early tumor development and metastasis of ovarian carcinoma. Moreover, we propose to employ recombinant METCAM/MUC18 proteins and other derived products as therapeutic agents to treat the ovarian cancer patients by decreasing the malignant potential of ovarian carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

METCAM/MUC18 Decreases the Malignant Propensity of Human Ovarian Carcinoma Cells

2018

IJMS

View full text Add to dashboard Cite

show abstract

“…Ovarian cancer is regarded as the most lethal gynecological cancer among the female population worldwide, and the role of lncRNAs in ovarian cancer has been well characterized. [20][21][22] In the current study, we unraveled the function of a novel lncRNA, TMPO-AS1, in ovarian cancer, which has not been discussed previously to our knowledge. We demonstrated that lncRNA TMPO-AS1 played an oncogenic role in ovarian cancer.…”

Section: Discussionmentioning

confidence: 87%

LncRNA TMPO‐AS1 promotes LCN2 transcriptional activity and exerts oncogenic functions in ovarian cancer

2020

View full text Add to dashboard Cite

Ovarian cancer remains the sixth most frequently occurring cancer in women worldwide. Long noncoding RNAs (lncRNAs) are capable of regulating gene expression, and thus, participating in a wide range of biological functions and disease processes including cancer development. Our work suggests that lncRNA TMPO antisense RNA 1 (TMPO‐AS1) represents an oncogenic lncRNA in ovarian cancer and presents a novel mechanism involving transcription factor E2F transcription factor 6 (E2F6) and lipocalin‐2 (LCN2). We identified upregulated lncRNA TMPO‐AS1 in ovarian cancer tissues and cells. siRNA‐mediated silencing of lncRNA TMPO‐AS1 restrained the aggressiveness of ovarian cancer cells and their pro‐angiogenic ability, and reduced the expression of LCN2. LncRNA TMPO‐AS1 was found to interact with E2F6, a transcriptional repressor that could bind to the promoter region of LCN2 gene. In addition, silencing of E2F6 or overexpression of LCN2 restored the aggressiveness of ovarian cancer cells and their pro‐angiogenic ability following siRNA‐mediated silencing of lncRNA TMPO‐AS1. Taken together, we demonstrated lncRNA TMPO‐AS1 could potentially promote LCN2 transcriptional activity by binding to transcription factor E2F6, and thus, stimulated the progression of ovarian cancer. These findings underscore a possible alternative therapeutic strategy for ovarian cancer treatment.

show abstract

“…Differential expression between tumor and non-tumor tissue at this gene has been founded in lung cancer [39] and ovarian cancer [40]. Anyhow, functional validation studies are needed to explore the mechanisms of the potential roles of these genes in risk of HBV-related HCC.…”

Section: Discussionmentioning

confidence: 99%

Knowledge-based analyses reveal new candidate genes associated with risk of hepatitis B virus related hepatocellular carcinoma

Jiang

Deng

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Recent genome-wide association studies (GWASs) have suggested several susceptibility loci of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) by statistical analysis at individual single-nucleotide polymorphisms (SNPs). However, these loci only explain a small fraction of HBV-related HCC heritability. In the present study, we aimed to identify additional susceptibility loci of HBV-related HCC using advanced knowledge-based analysis.Methods: We performed knowledge-based analysis (including gene- and gene-set-based association tests) on variant-level association p-values from two existing GWASs of HBV-related HCC. Five different types of gene-sets were collected for the association analysis. A number of SNPs within the gene prioritized by the knowledge-based association tests were selected to replicate genetic associations in an independent sample of 965 cases and 923 controls.Results: The gene-based association analysis detected four genes significantly or suggestively associated with HBV-related HCC risk: SLC39A8, GOLGA8M, SMIM31, and WHAMMP2. The gene-set-based association analysis prioritized two promising gene set for HCC, cell cycle G1/S transition and NOTCH1 intracellular domain regulates transcription. Within the gene sets, three promising candidate genes (CDC45, NCOR1 and KAT2A) were further prioritized for HCC. Among genes of liver-specific expression, multiple genes previously implicated in HCC were also highlighted. However, probably due to small sample size, none of the genes prioritized by the knowledge-based association analyses were successfully replicated in the independent sample. Conclusions: This comprehensive knowledge-based association mining study suggested several promising genes and gene-sets associated with HBV-related HCC risks, which would facilitate follow-up functional studies on the pathogenic mechanism of HCC.

show abstract

Long non-coding RNAs in ovarian cancer

Cited by 80 publications

References 114 publications

METCAM/MUC18 Decreases the Malignant Propensity of Human Ovarian Carcinoma Cells

METCAM/MUC18 Decreases the Malignant Propensity of Human Ovarian Carcinoma Cells

LncRNA TMPO‐AS1 promotes LCN2 transcriptional activity and exerts oncogenic functions in ovarian cancer

Knowledge-based analyses reveal new candidate genes associated with risk of hepatitis B virus related hepatocellular carcinoma

Contact Info

Product

Resources

About